Form 4 for STRO SUTRO BIOPHARMA, INC.
Accepted 2022-01-03 00:00:00 ET · period of report 2021-12-30 · accession 0001209191-22-000329 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2022-01-03 | 2021-12-30 | STRO | NEWELL WILLIAM J | CEO, Dir | J - Other | $0.00 | -24.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-30 | J | A | 1,863 | $0.00 | 106,525 | I By William J. Newell Family Trust DTD 03/15/2019 | — | — | (F3) Represents shares received as a liquidating distribution from Taluswood. (F4) The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. |
| 2 | Common | Common Stock | 2021-12-30 | J | D | 26,091 | $0.00 | 0 | I By Taluswood Partners, L.P. | — | — | (F2) The reporting person is the general partner of Taluswood. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |